About B-MoGen
B-MoGen is a company based in Minneapolis (United States) founded in 2015 was acquired by Bio-Techne in June 2019.. B-MoGen has raised $1.03 million across 5 funding rounds from investors including Bio-Techne and HHS. B-MoGen offers products and services including TcBuster, Recombinant Proteins, Antibodies, ELISAs, and Luminex Assays. B-MoGen operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
- Headquarter Minneapolis, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name R&D Systems, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.03 M (USD)
in 5 rounds
-
Latest Funding Round
$188.54 K (USD), Grant
Aug 15, 2018
-
Investors
Bio-Techne
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Bio-Techne
(Jun 04, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of B-MoGen
B-MoGen offers a comprehensive portfolio of products and services, including TcBuster, Recombinant Proteins, Antibodies, ELISAs, and Luminex Assays. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Non-viral system for stable gene transfer in cell therapies
Proteins for biological assays and cell culture applications
Used in ELISAs and immunoassays for protein detection
Kits for measuring proteins in research and diagnostics
Platforms for simultaneous biomarker analysis in workflows
Funding Insights of B-MoGen
B-MoGen has successfully raised a total of $1.03M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $188.54 thousand completed in August 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $188,543
-
First Round
First Round
(02 May 2016)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2018 | Amount | Grant - B-MoGen | Valuation |
investors |
|
| Aug, 2018 | Amount | Grant - B-MoGen | Valuation |
investors |
|
| Aug, 2017 | Amount | Grant - B-MoGen | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in B-MoGen
B-MoGen has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Bio-Techne and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Developer of biotech reagents, instruments and clinical diagnostic products
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by B-MoGen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - B-MoGen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
B-Mogen Comparisons
Competitors of B-MoGen
B-MoGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on B-Mogen
Frequently Asked Questions about B-MoGen
When was B-MoGen founded?
B-MoGen was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is B-MoGen located?
B-MoGen is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
Is B-MoGen a funded company?
B-MoGen is a funded company, having raised a total of $1.03M across 5 funding rounds to date. The company's 1st funding round was a Grant of $224.56K, raised on May 02, 2016.
What does B-MoGen do?
B-MoGen was founded in 2015 in Minneapolis, United States, within the biotechnology sector focused on genetic technologies. The Sleeping Beauty transposon system is utilized to create solutions that facilitate gene delivery in challenging cell types, such as primary cells. Enhancements to gene expression duration are provided, alongside services for custom vector production and targeted genome modifications. Operations emphasize practical applications in research and therapeutic development.
Who are the top competitors of B-MoGen?
B-MoGen's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does B-MoGen offer?
B-MoGen offers TcBuster, Recombinant Proteins, Antibodies, ELISAs, and Luminex Assays.
Who are B-MoGen's investors?
B-MoGen has 2 investors. Key investors include Bio-Techne, and HHS.